Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06154278 · ClinicalTrials.gov registry record · Phase 2

Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B

A Phase 2 study of Chronic Hepatitis B, sponsored by University of Maryland, Baltimore.

Recruiting
Registry status
Phase 2
Development phase
10
Enrollment target
1
Study location

NCT06154278: Recruiting Phase 2 study of Chronic Hepatitis B, sponsored by University of Maryland, Baltimore.

NCT06154278 is a Phase 2 study of Chronic Hepatitis B that is actively recruiting participants, run by University of Maryland, Baltimore. The registered enrollment target is 10 participants, below the 293-participant average among 14 other Chronic Hepatitis B trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06154278, a Phase 2 study of Chronic Hepatitis B, is actively recruiting participants, sponsored by University of Maryland, Baltimore.

RECRUITING
Registry status
Phase 2
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to learn about the action of Imdusiran (AB-729) in the liver of people with chronic hepatitis B. The main questions it aims to answer are: * how well is it working in the liver * how does Imdusiran affect the hepatitis B virus Participants will receive injections of Imdusiran, one injection every 8 weeks, for a total of 4 doses. They will also undergo 2 liver biopsies: one with the first dose of Imdusiran, and the second 8 weeks after the last dose of Imdusiran.

Primary Outcome

Intrahepatic drug concentration at day 0 (peak) and week 32 (trough)

Conditions Studied

Interventions

  • DRUG Imdusiran (AB-729)

Study Locations (1)

Maryland

  • Institute of Human Virology, University of Maryland School of Medicine - Baltimore

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2024-07-25
Est. Completion 2027-07-01
Phase Phase 2
University of Maryland, Baltimore

560 total trials

What NCT06154278 shows while recruiting

NCT06154278 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 293-participant average among 14 other Chronic Hepatitis B trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Chronic Hepatitis B appearing as the primary indexed condition, and to 1 intervention - of which Imdusiran (AB-729) is the first listed.

NCT06154278 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT06154278 about?

NCT06154278 is a clinical study titled "Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B". The goal of this clinical trial is to learn about the action of Imdusiran (AB-729) in the liver of people with chronic hepatitis B. The main questions it aims to answer are: * how well is it working in the liver * how does Imdusiran affect the hepatitis B virus Participants will receive injections...

What is the current status of trial NCT06154278?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2024-07-25. Estimated completion is 2027-07-01.

What conditions does trial NCT06154278 study?

This clinical trial studies the following conditions: Chronic Hepatitis B.

What interventions are being tested in trial NCT06154278?

The interventions under investigation include: Imdusiran (AB-729) (DRUG).

Who is sponsoring clinical trial NCT06154278?

This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06154278 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Hepatitis B

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06154278's enrollment target sits among peer trials

10 14th of 14 the lowest of 14 other Chronic Hepatitis B trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Hepatitis B trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06154278, the US trial registry maintained by the National Library of Medicine. NCT06154278 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.